(Total Views: 179)
Posted On: 04/24/2024 5:57:46 PM
Post# of 90
NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV formulation of suramin. According to the announcement, the company has completed execution of three pivotal registration/validation batches of PAX-101. The company noted that the completion is an “important milestone” in enabling a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (FDA), which it plans to complete by the last quarter of 2024. The NDA, along with the approval of the FDA, is a strategic step in the company’s efforts to make the first and only form of suramin for the treatment of stage 1 Human African Trypanosomiasis (“HAT”) available commercially in the United States. HAT is caused by Trypanosoma brucei rhodesiense, a fatal, neglected tropical disease.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV formulation of suramin. According to the announcement, the company has completed execution of three pivotal registration/validation batches of PAX-101. The company noted that the completion is an “important milestone” in enabling a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administration (FDA), which it plans to complete by the last quarter of 2024. The NDA, along with the approval of the FDA, is a strategic step in the company’s efforts to make the first and only form of suramin for the treatment of stage 1 Human African Trypanosomiasis (“HAT”) available commercially in the United States. HAT is caused by Trypanosoma brucei rhodesiense, a fatal, neglected tropical disease.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
